dexamethasone phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
3920 2392-39-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dexamethasone phosphate
  • dexamethasone sodium phosphate
  • decadron
  • dexamethasone phosphoric acid
An anti-inflammatory 9-fluoro-glucocorticoid
  • Molecular weight: 472.45
  • Formula: C22H30FO8P
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 141.36
  • ALOGS: -2.21
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.08 mg/mL Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 81 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,ZAP70 45
kinase-selectivity-class AXL,CDK4,CDK9,GRK2,MAP2K6,SYK,TEK,ZAP70 8
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.296 Moderate 0.78
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.78
rat-kpuu-brain Rat brain Kpuu 0.002 % Moderate 0.78

Approvals:

DateAgencyCompanyOrphan
Sept. 2, 1959 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count decreased 397.31 12.34 231 20569 71301 90536346
Myelosuppression 255.63 12.34 157 20643 53434 90554213
Febrile neutropenia 242.83 12.34 236 20564 158113 90449534
Platelet count decreased 221.03 12.34 210 20590 136759 90470888
White blood cell count decreased 186.12 12.34 210 20590 166899 90440748
Interstitial lung disease 142.28 12.34 127 20673 76278 90531369
Hepatic function abnormal 115.23 12.34 91 20709 46197 90561450
Neutropenia 110.99 12.34 191 20609 224713 90382934
Anaemia 107.88 12.34 245 20555 352557 90255090
Anaphylactic shock 96.01 12.34 70 20730 31547 90576100
Bone marrow failure 88.14 12.34 67 20733 32154 90575493
Hypokalaemia 74.89 12.34 119 20681 130997 90476650
Thrombocytopenia 69.37 12.34 150 20650 208575 90399072
Pyrexia 69.12 12.34 317 20483 660168 89947479
Pneumocystis jirovecii pneumonia 68.23 12.34 49 20751 21567 90586080
Hypoalbuminaemia 66.76 12.34 43 20757 15854 90591793
Neuropathy peripheral 65.76 12.34 115 20685 136855 90470792
Colony stimulating factor therapy 65.74 12.34 16 20784 408 90607239
Lymphocyte count decreased 60.76 12.34 56 20744 34994 90572653
Malignant neoplasm progression 59.65 12.34 96 20704 106774 90500873
Disease progression 59.57 12.34 119 20681 156496 90451151
Cytokine release syndrome 59.10 12.34 50 20750 27923 90579724
Acute lymphocytic leukaemia recurrent 57.00 12.34 22 20778 2699 90604948
Product use in unapproved indication 53.33 12.34 184 20616 336052 90271595
Alanine aminotransferase increased 52.49 12.34 96 20704 118242 90489405
Leukopenia 48.90 12.34 85 20715 100625 90507022
Neoplasm recurrence 46.48 12.34 20 20780 3239 90604408
Decreased appetite 46.36 12.34 190 20610 376350 90231297
Hypocalcaemia 44.95 12.34 52 20748 42316 90565331
Off label use 43.03 12.34 413 20387 1101839 89505808
Aortitis 39.67 12.34 14 20786 1336 90606311
Drug hypersensitivity 37.31 12.34 31 20769 463578 90144069
Joint swelling 36.54 12.34 37 20763 503263 90104384
Aspartate aminotransferase increased 36.49 12.34 76 20724 102861 90504786
Neoplasm progression 35.00 12.34 47 20753 44439 90563208
Tumour lysis syndrome 34.55 12.34 25 20775 11127 90596520
Disseminated intravascular coagulation 32.73 12.34 32 20768 21506 90586141
Triple negative breast cancer 32.27 12.34 9 20791 395 90607252
Radiation necrosis 31.86 12.34 10 20790 663 90606984
Enterocolitis 31.33 12.34 23 20777 10467 90597180
Hypoproteinaemia 31.25 12.34 15 20785 3127 90604520
Allergy test positive 30.90 12.34 10 20790 732 90606915
Respiratory failure 29.39 12.34 76 20724 118342 90489305
Product dose omission issue 28.11 12.34 16 20784 291671 90315976
Neurotoxicity 27.35 12.34 29 20771 21438 90586209
Klebsiella infection 27.25 12.34 21 20779 10276 90597371
Drug ineffective for unapproved indication 26.96 12.34 52 20748 66592 90541055
Hydrocephalus 26.87 12.34 17 20783 6077 90601570
Central nervous system infection 25.37 12.34 9 20791 872 90606775
Chemotherapy 25.36 12.34 11 20789 1816 90605831
Eastern Cooperative Oncology Group performance status worsened 24.73 12.34 11 20789 1928 90605719
Renal vein thrombosis 24.52 12.34 8 20792 601 90607046
Anorectal disorder 24.24 12.34 11 20789 2020 90605627
Sepsis 23.90 12.34 93 20707 179721 90427926
Left ventricular dilatation 23.83 12.34 8 20792 657 90606990
Brain abscess 23.72 12.34 12 20788 2800 90604847
Hyperglycaemia 23.41 12.34 42 20758 50928 90556719
Posterior reversible encephalopathy syndrome 22.99 12.34 27 20773 22312 90585335
Cytopenia 22.99 12.34 24 20776 17425 90590222
Procedural vomiting 22.47 12.34 8 20792 783 90606864
Musculoskeletal stiffness 22.42 12.34 21 20779 296511 90311136
Granulocyte count decreased 22.27 12.34 11 20789 2441 90605206
Arthropathy 22.20 12.34 31 20769 366211 90241436
Fibromyalgia 21.83 12.34 10 20790 206259 90401388
Fall 21.79 12.34 49 20751 481761 90125886
Necrotising colitis 21.71 12.34 9 20791 1329 90606318
Small intestinal perforation 21.62 12.34 10 20790 1919 90605728
Gait disturbance 21.45 12.34 17 20783 260479 90347168
Gastrointestinal perforation 21.42 12.34 13 20787 4319 90603328
Multiple organ dysfunction syndrome 21.40 12.34 48 20752 68288 90539359
Hyperuricaemia 20.67 12.34 15 20785 6704 90600943
Constipation 20.47 12.34 122 20678 280273 90327374
Stomatitis 20.36 12.34 120 20680 274578 90333069
Hyperpyrexia 20.29 12.34 13 20787 4748 90602899
Osteonecrosis of jaw 20.28 12.34 34 20766 39069 90568578
Arthralgia 20.21 12.34 101 20699 778421 89829226
Memory impairment 20.20 12.34 10 20790 197234 90410413
Hyponatraemia 20.18 12.34 72 20728 133466 90474181
Systemic candida 19.80 12.34 13 20787 4946 90602701
Arteritis 19.63 12.34 7 20793 688 90606959
Erythema 19.54 12.34 104 20696 229142 90378505
Nausea 19.48 12.34 360 20440 1109956 89497691
Pancytopenia 19.18 12.34 66 20734 120197 90487450
Steroid diabetes 19.15 12.34 10 20790 2492 90605155
Light chain analysis abnormal 18.81 12.34 5 20795 183 90607464
Myelopathy 18.76 12.34 11 20789 3433 90604214
Hypochloraemia 18.71 12.34 10 20790 2612 90605035
Abdominal discomfort 18.15 12.34 53 20747 477275 90130372
Plasma cell myeloma 17.93 12.34 33 20767 40795 90566852
Peripheral swelling 17.88 12.34 43 20757 413063 90194584
Glossodynia 17.79 12.34 29 20771 321750 90285897
Large intestine perforation 17.77 12.34 16 20784 9696 90597951
Pain 17.33 12.34 146 20654 996195 89611452
Arteriovenous malformation 17.24 12.34 8 20792 1547 90606100
Rheumatoid arthritis 17.11 12.34 36 20764 362578 90245069
Gamma-glutamyltransferase increased 17.08 12.34 31 20769 37921 90569726
Ileus 17.03 12.34 20 20780 16526 90591121
Dermatitis acneiform 16.90 12.34 13 20787 6341 90601306
Septic shock 16.89 12.34 50 20750 84110 90523537
Blood lactate dehydrogenase increased 16.84 12.34 25 20775 25907 90581740
Cerebral venous sinus thrombosis 16.78 12.34 9 20791 2367 90605280
Fatigue 16.71 12.34 177 20623 1153846 89453801
Erythema multiforme 16.41 12.34 17 20783 12229 90595418
Metastases to central nervous system 16.09 12.34 20 20780 17522 90590125
Procedural nausea 15.99 12.34 7 20793 1181 90606466
Pain in extremity 15.72 12.34 52 20748 450477 90157170
Protein total decreased 15.65 12.34 13 20787 7076 90600571
Gait inability 15.65 12.34 7 20793 146449 90461198
Phaeochromocytoma crisis 15.42 12.34 5 20795 368 90607279
Alopecia areata 15.27 12.34 8 20792 2007 90605640
Bacteraemia 15.21 12.34 22 20778 22278 90585369
Vomiting 14.99 12.34 259 20541 788034 89819613
Hypomagnesaemia 14.67 12.34 28 20772 35560 90572087
Drug ineffective 14.60 12.34 227 20573 1384071 89223576
Hypertriglyceridaemia 14.44 12.34 13 20787 7876 90599771
Haematotoxicity 14.34 12.34 16 20784 12519 90595128
Peritonitis 14.26 12.34 20 20780 19685 90587962
Blood bilirubin increased 14.13 12.34 31 20769 43439 90564208
COVID-19 pneumonia 13.98 12.34 19 20781 18158 90589489
Loss of personal independence in daily activities 13.78 12.34 7 20793 136098 90471549
Cerebral infarction 13.62 12.34 23 20777 26573 90581074
Meningitis bacterial 13.54 12.34 7 20793 1710 90605937
Plasma cell myeloma refractory 13.50 12.34 6 20794 1050 90606597
Mobility decreased 13.48 12.34 23 20777 250711 90356936
Marginal zone lymphoma stage III 13.48 12.34 3 20797 51 90607596
Angioedema 13.46 12.34 39 20761 64837 90542810
Dysentery 13.36 12.34 6 20794 1076 90606571
Venoocclusive liver disease 13.25 12.34 11 20789 5982 90601665
Diffuse large B-cell lymphoma refractory 13.22 12.34 7 20793 1793 90605854
Toxicity to various agents 13.22 12.34 29 20771 287817 90319830
Rheumatoid factor positive 13.15 12.34 12 20788 171638 90436009
Periodontitis 12.77 12.34 9 20791 3844 90603803
Muscle spasms 12.74 12.34 24 20776 251859 90355788
Blood phosphorus decreased 12.74 12.34 10 20790 5024 90602623
Hand deformity 12.69 12.34 31 20769 296331 90311316
Peripheral sensory neuropathy 12.68 12.34 13 20787 9237 90598410
Arthritis 12.46 12.34 12 20788 167303 90440344

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count decreased 247.34 15.04 209 17868 63206 42540052
Myelosuppression 237.65 15.04 170 17907 40291 42562967
Platelet count decreased 197.09 15.04 267 17810 138314 42464944
Choroiditis 177.68 15.04 51 18026 1324 42601934
White blood cell count decreased 169.62 15.04 221 17856 110175 42493083
Endophthalmitis 167.29 15.04 65 18012 4368 42598890
Febrile neutropenia 158.89 15.04 283 17794 185420 42417838
Intraocular pressure increased 137.61 15.04 63 18014 6370 42596888
Interstitial lung disease 90.44 15.04 137 17940 78325 42524933
Eye pain 89.56 15.04 67 18010 16963 42586295
Uveitis 88.93 15.04 53 18024 9205 42594053
Neutropenia 84.24 15.04 229 17848 199202 42404056
Visual acuity reduced 79.08 15.04 63 18014 17487 42585771
Hypoalbuminaemia 72.40 15.04 57 18020 15553 42587705
Lymphocyte count decreased 68.34 15.04 71 18006 27738 42575520
Disseminated intravascular coagulation 65.83 15.04 66 18011 24728 42578530
Tumour lysis syndrome 62.40 15.04 61 18016 22170 42581088
Hepatic function abnormal 62.18 15.04 92 17985 51475 42551783
Pyrexia 60.33 15.04 327 17750 393715 42209543
Neoplasm progression 58.96 15.04 67 18010 28933 42574325
Decreased appetite 53.80 15.04 192 17885 192945 42410313
Coombs positive haemolytic anaemia 53.38 15.04 20 18057 1215 42602043
Anaemia 52.97 15.04 247 17830 280031 42323227
Large intestine perforation 46.78 15.04 36 18041 9500 42593758
Off label use 46.72 15.04 443 17634 637892 41965366
Hypokalaemia 46.03 15.04 97 17980 71624 42531634
Hiccups 45.06 15.04 39 18038 12132 42591126
Lymphadenitis 42.69 15.04 21 18056 2490 42600768
Bone marrow failure 41.26 15.04 60 18017 33033 42570225
Drug interaction 40.98 15.04 32 18045 266967 42336291
Anaphylactic shock 40.62 15.04 50 18027 23467 42579791
Product use in unapproved indication 40.41 15.04 170 17907 184286 42418972
Toxicity to various agents 38.39 15.04 25 18052 229111 42374147
Thrombocytopenia 36.09 15.04 168 17909 190111 42413147
Fall 32.46 15.04 31 18046 234489 42368769
Stomatitis 31.04 15.04 67 18010 50262 42552996
Cytokine release syndrome 30.64 15.04 62 18015 44465 42558793
Immune effector cell-associated neurotoxicity syndrome 30.43 15.04 28 18049 9433 42593825
Malignant neoplasm progression 30.32 15.04 108 17969 108292 42494966
Migraine with aura 29.52 15.04 12 18065 907 42602351
Septic shock 28.84 15.04 95 17982 91577 42511681
Drug abuse 28.56 15.04 5 18072 104766 42498492
Aspartate aminotransferase increased 27.98 15.04 84 17993 77079 42526179
Disease progression 27.33 15.04 127 17950 143529 42459729
Neuropathy peripheral 26.39 15.04 99 17978 101754 42501504
Strongyloidiasis 26.25 15.04 17 18060 3414 42599844
Myocardial infarction 26.05 15.04 10 18067 123999 42479259
Overflow diarrhoea 25.97 15.04 6 18071 63 42603195
Blood lactate dehydrogenase increased 25.12 15.04 42 18035 26039 42577219
Pneumonia bacterial 24.92 15.04 32 18045 15660 42587598
Hyperglycaemia 24.86 15.04 58 18019 45801 42557457
Infusion related reaction 24.75 15.04 69 18008 60737 42542521
Alanine aminotransferase increased 24.64 15.04 88 17989 88318 42514940
Hypotension 24.46 15.04 45 18032 257586 42345672
Gastrointestinal perforation 24.36 15.04 18 18059 4468 42598790
Product dose omission issue 24.29 15.04 18 18059 154347 42448911
Muscle spasms 23.68 15.04 4 18073 86040 42517218
JC virus infection 23.27 15.04 15 18062 2989 42600269
Capillary nail refill test abnormal 22.54 15.04 5 18072 43 42603215
Periodontitis 22.12 15.04 13 18064 2198 42601060
Hypocalcaemia 21.94 15.04 43 18034 30130 42573128
Pneumocystis jirovecii pneumonia 20.93 15.04 38 18039 25143 42578115
Haemolysis 20.93 15.04 23 18054 9566 42593692
Cerebrovascular accident 20.13 15.04 8 18069 97152 42506106
Tumour necrosis 20.04 15.04 11 18066 1633 42601625
Confusional state 20.02 15.04 25 18052 167572 42435686
Cytomegalovirus chorioretinitis 19.59 15.04 16 18061 4595 42598663
Hypoproteinaemia 19.25 15.04 13 18064 2799 42600459
Drug-induced liver injury 19.23 15.04 47 18030 38226 42565032
Dizziness 19.13 15.04 49 18028 249205 42354053
Somnolence 19.09 15.04 19 18058 141086 42462172
Paronychia 18.58 15.04 15 18062 4240 42599018
Overdose 18.27 15.04 11 18066 105253 42498005
Fatigue 17.88 15.04 110 17967 435531 42167727
Conjunctival hyperaemia 17.82 15.04 13 18064 3163 42600095
Cardiac failure congestive 17.81 15.04 7 18070 85595 42517663
Granulocyte count decreased 17.76 15.04 10 18067 1560 42601698
Eye complication associated with device 17.76 15.04 3 18074 4 42603254
Dermatitis acneiform 17.65 15.04 19 18058 7720 42595538
Arthralgia 17.62 15.04 38 18039 205200 42398058
Systemic candida 17.61 15.04 16 18061 5303 42597955
Progressive multifocal leukoencephalopathy 17.50 15.04 23 18054 11513 42591745
PaO2/FiO2 ratio decreased 17.49 15.04 4 18073 40 42603218
Renal ischaemia 17.19 15.04 10 18067 1660 42601598
Joint swelling 16.96 15.04 4 18073 68018 42535240
Pulmonary artery thrombosis 16.88 15.04 8 18069 874 42602384
IVth nerve paralysis 16.56 15.04 7 18070 584 42602674
Uveitis-glaucoma-hyphaema syndrome 16.40 15.04 3 18074 8 42603250
Peripheral swelling 16.28 15.04 9 18068 90261 42512997
Headache 16.18 15.04 50 18027 239319 42363939
Plasma cell myeloma refractory 16.00 15.04 9 18068 1401 42601857
Splenic abscess 15.84 15.04 7 18070 651 42602607
Hypogammaglobulinaemia 15.46 15.04 22 18055 11869 42591389
Pneumonia 15.10 15.04 257 17820 421892 42181366
Renal impairment 15.10 15.04 89 17988 110139 42493119
Angle closure glaucoma 15.05 15.04 8 18069 1114 42602144

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neutrophil count decreased 614.63 11.65 419 35452 120522 110432906
Myelosuppression 481.85 11.65 328 35543 94012 110459416
Platelet count decreased 436.34 11.65 451 35420 229992 110323436
Febrile neutropenia 392.95 11.65 498 35373 316269 110237159
White blood cell count decreased 350.36 11.65 401 35470 228989 110324439
Interstitial lung disease 198.12 11.65 235 35636 139099 110414329
Neutropenia 179.16 11.65 383 35488 374237 110179191
Choroiditis 178.49 11.65 50 35821 1565 110551863
Hepatic function abnormal 178.13 11.65 180 35691 89115 110464313
Hypoalbuminaemia 150.73 11.65 102 35769 28872 110524556
Anaemia 149.12 11.65 452 35419 546634 110006794
Endophthalmitis 145.56 11.65 65 35806 8122 110545306
Bone marrow failure 125.31 11.65 122 35749 57726 110495702
Lymphocyte count decreased 124.51 11.65 121 35750 57122 110496306
Anaphylactic shock 117.86 11.65 112 35759 51434 110501994
Intraocular pressure increased 116.44 11.65 61 35810 10815 110542613
Hypokalaemia 115.47 11.65 210 35661 182238 110371190
Pyrexia 113.94 11.65 583 35288 897682 109655746
Tumour lysis syndrome 102.79 11.65 83 35788 30718 110522710
Thrombocytopenia 100.31 11.65 294 35577 348591 110204837
Malignant neoplasm progression 99.33 11.65 192 35679 174375 110379053
Disseminated intravascular coagulation 98.78 11.65 92 35779 41194 110512234
Product use in unapproved indication 95.13 11.65 340 35531 447037 110106391
Decreased appetite 92.27 11.65 351 35520 475495 110077933
Neuropathy peripheral 86.32 11.65 184 35687 179093 110374335
Cytokine release syndrome 86.00 11.65 110 35761 70196 110483232
Off label use 85.22 11.65 799 35072 1499386 109054042
Neoplasm progression 78.90 11.65 101 35770 64494 110488934
Pneumocystis jirovecii pneumonia 77.69 11.65 82 35789 42653 110510775
Visual acuity reduced 75.63 11.65 71 35800 32102 110521326
Joint swelling 75.13 11.65 25 35846 442820 110110608
Alanine aminotransferase increased 71.12 11.65 173 35698 183600 110369828
Disease progression 70.41 11.65 206 35665 243828 110309600
Hypocalcaemia 70.26 11.65 96 35775 65270 110488158
Colony stimulating factor therapy 66.97 11.65 19 35852 623 110552805
Triple negative breast cancer 65.83 11.65 18 35853 514 110552914
Peripheral swelling 63.15 11.65 26 35845 404008 110149420
Large intestine perforation 62.35 11.65 48 35823 16581 110536847
Aspartate aminotransferase increased 62.34 11.65 151 35720 159785 110393643
Arthralgia 59.51 11.65 101 35770 779531 109773897
Uveitis 59.04 11.65 52 35819 21658 110531770
Hiccups 56.86 11.65 41 35830 12828 110540600
Rheumatoid arthritis 56.15 11.65 14 35857 299599 110253829
Eye pain 54.48 11.65 74 35797 50025 110503403
Drug hypersensitivity 54.02 11.65 41 35830 454049 110099379
Coombs positive haemolytic anaemia 53.84 11.65 20 35851 1557 110551871
Fatigue 52.53 11.65 210 35661 1215748 109337680
Toxicity to various agents 51.50 11.65 48 35823 480507 110072921
Fall 50.95 11.65 73 35798 603409 109950019
Septic shock 50.31 11.65 138 35733 157390 110396038
Arthropathy 49.14 11.65 16 35855 287506 110265922
Hyperglycaemia 48.86 11.65 94 35777 84996 110468432
Hypoproteinaemia 48.85 11.65 28 35843 5917 110547511
Acute lymphocytic leukaemia recurrent 46.87 11.65 27 35844 5760 110547668
Pain 45.71 11.65 158 35713 954797 109598631
Confusional state 44.38 11.65 52 35819 468628 110084800
Leukopenia 44.23 11.65 127 35744 148664 110404764
Synovitis 42.23 11.65 18 35853 274074 110279354
Immune effector cell-associated neurotoxicity syndrome 41.38 11.65 36 35835 14746 110538682
Neoplasm recurrence 41.28 11.65 24 35847 5208 110548220
Drug ineffective for unapproved indication 41.03 11.65 98 35773 102740 110450688
Gastrointestinal perforation 40.57 11.65 27 35844 7429 110545999
Glossodynia 40.39 11.65 11 35860 221993 110331435
Overdose 39.96 11.65 13 35858 233781 110319647
Hyperuricaemia 39.90 11.65 35 35836 14496 110538932
Strongyloidiasis 39.68 11.65 23 35848 4963 110548465
Klebsiella infection 39.25 11.65 40 35831 19969 110533459
Product dose omission issue 38.31 11.65 29 35842 321753 110231675
Peripheral sensory neuropathy 37.65 11.65 36 35835 16644 110536784
Lymphadenitis 37.62 11.65 23 35848 5470 110547958
Enterocolitis 37.39 11.65 38 35833 18911 110534517
Blood lactate dehydrogenase increased 37.29 11.65 58 35813 44276 110509152
Granulocyte count decreased 36.13 11.65 20 35851 3954 110549474
Drug abuse 35.83 11.65 7 35864 177404 110376024
Aortitis 35.82 11.65 16 35855 1999 110551429
Systemic candida 35.67 11.65 28 35843 9946 110543482
Gamma-glutamyltransferase increased 34.30 11.65 67 35804 61242 110492186
Nasopharyngitis 32.96 11.65 48 35823 394313 110159115
Plasma cell myeloma refractory 32.76 11.65 15 35856 1986 110551442
Drug interaction 32.68 11.65 71 35800 500112 110053316
Hand deformity 32.63 11.65 15 35856 218491 110334937
Sinusitis 32.51 11.65 29 35842 296659 110256769
Musculoskeletal stiffness 32.32 11.65 26 35845 279796 110273632
Weight increased 32.29 11.65 54 35817 419590 110133838
Anti-cyclic citrullinated peptide antibody positive 31.31 11.65 10 35861 181974 110371454
Periodontitis 31.12 11.65 20 35851 5188 110548240
Neurotoxicity 31.11 11.65 52 35819 42155 110511273
Constipation 30.72 11.65 210 35661 357576 110195852
Muscle spasms 30.71 11.65 27 35844 278130 110275298
Myocardial infarction 30.57 11.65 12 35859 192071 110361357
Pain in extremity 30.31 11.65 71 35800 487047 110066381
Contraindicated product administered 30.03 11.65 22 35849 248245 110305183
Aspergillus infection 29.63 11.65 39 35832 25577 110527851
Hypochloraemia 29.62 11.65 17 35854 3601 110549827
Multiple organ dysfunction syndrome 29.38 11.65 112 35759 151598 110401830
Bronchopulmonary aspergillosis 29.31 11.65 42 35829 29821 110523607
Sepsis 29.22 11.65 194 35677 327152 110226276
Swelling 29.06 11.65 43 35828 350998 110202430
Cytopenia 29.04 11.65 42 35829 30074 110523354
Allergy test positive 28.94 11.65 11 35860 912 110552516
Pneumonia bacterial 28.86 11.65 39 35832 26222 110527206
Memory impairment 28.66 11.65 14 35857 196930 110356498
Fibromyalgia 28.34 11.65 10 35861 170899 110382529
Cerebral infarction 28.21 11.65 56 35815 51782 110501646
Dermatitis acneiform 27.90 11.65 27 35844 12668 110540760
Pemphigus 27.29 11.65 18 35853 214552 110338876
Pericarditis 27.04 11.65 19 35852 219095 110334333
Tumour necrosis 27.04 11.65 14 35857 2422 110551006
Posterior reversible encephalopathy syndrome 26.69 11.65 43 35828 33818 110519610
Small intestinal perforation 26.63 11.65 17 35854 4359 110549069
Diffuse large B-cell lymphoma refractory 26.58 11.65 14 35857 2507 110550921
Osteoarthritis 26.55 11.65 13 35858 182610 110370818
Systemic lupus erythematosus 26.52 11.65 26 35845 254312 110299116
Abdominal discomfort 26.48 11.65 55 35816 393803 110159625
Headache 26.30 11.65 173 35698 882204 109671224
Radiation necrosis 26.14 11.65 10 35861 844 110552584
Drug intolerance 25.49 11.65 59 35812 406453 110146975
Cytomegalovirus chorioretinitis 25.47 11.65 20 35851 7108 110546320
Anorectal disorder 25.40 11.65 14 35857 2745 110550683
Mobility decreased 25.07 11.65 24 35847 237398 110316030
COVID-19 pneumonia 25.06 11.65 44 35827 37099 110516329
Helicobacter infection 24.89 11.65 14 35857 181863 110371565
Hydrocephalus 24.58 11.65 23 35848 10352 110543076
Respiratory failure 24.53 11.65 136 35735 215196 110338232
Cytomegalovirus infection reactivation 24.51 11.65 30 35841 18303 110535125
Loss of personal independence in daily activities 24.49 11.65 9 35862 150011 110403417
Wound 24.40 11.65 24 35847 234413 110319015
Hypogammaglobulinaemia 23.89 11.65 31 35840 20045 110533383
Venoocclusive liver disease 23.84 11.65 27 35844 15180 110538248
Peritonitis 23.80 11.65 40 35831 32567 110520861
Blood cholinesterase decreased 23.74 11.65 8 35863 468 110552960
Protein total decreased 23.63 11.65 23 35848 10867 110542561
Arteritis 23.44 11.65 10 35861 1119 110552309
Anxiety 23.35 11.65 48 35823 345030 110208398
Bacteraemia 23.32 11.65 46 35825 42344 110511084
Hyperpyrexia 23.29 11.65 20 35851 8049 110545379
Paronychia 23.29 11.65 23 35848 11058 110542370
Pneumonia 23.14 11.65 406 35465 876308 109677120
Nausea 22.96 11.65 543 35328 1235147 109318281
Chemotherapy 22.86 11.65 12 35859 2134 110551294
Ileus 22.83 11.65 38 35833 30691 110522737
Necrotising colitis 22.09 11.65 11 35860 1754 110551674
Muscle injury 22.07 11.65 9 35862 140798 110412630
Pancytopenia 21.66 11.65 129 35742 209484 110343944
Osteonecrosis of jaw 21.62 11.65 48 35823 47969 110505459
Erythema 21.51 11.65 165 35706 291282 110262146
Blood pressure decreased 21.49 11.65 84 35787 115007 110438421
Hypomagnesaemia 21.40 11.65 55 35816 60315 110493113
Adrenal insufficiency 20.94 11.65 44 35827 42346 110511082
Gait inability 20.92 11.65 9 35862 136367 110417061
Dizziness 20.72 11.65 137 35734 698056 109855372
Myelopathy 20.69 11.65 16 35855 5560 110547868
Psoriatic arthropathy 20.64 11.65 20 35851 196741 110356687
Overflow diarrhoea 20.48 11.65 6 35865 221 110553207
Night sweats 20.30 11.65 9 35862 133974 110419454
Gait disturbance 20.29 11.65 37 35834 278171 110275257
Light chain analysis abnormal 20.25 11.65 6 35865 230 110553198
Lip dry 20.10 11.65 4 35867 100079 110453349
Pulmonary artery thrombosis 20.09 11.65 10 35861 1592 110551836
Folliculitis 20.08 11.65 15 35856 167638 110385790
Arthritis 20.07 11.65 15 35856 167571 110385857
Globulins decreased 19.99 11.65 8 35863 761 110552667
Stomatitis 19.94 11.65 153 35718 270089 110283339
Capillary nail refill test abnormal 19.93 11.65 5 35866 101 110553327
Fibrin D dimer increased 19.89 11.65 20 35851 9825 110543603
Cerebrovascular accident 19.52 11.65 18 35853 181266 110372162
Renal impairment 19.49 11.65 116 35755 188329 110365099
Hypophosphataemia 19.46 11.65 37 35834 33145 110520283
Central nervous system infection 19.36 11.65 10 35861 1722 110551706
Eastern Cooperative Oncology Group performance status worsened 19.24 11.65 12 35859 2957 110550471
Treatment failure 19.23 11.65 38 35833 277196 110276232
Blood cholesterol increased 19.13 11.65 19 35852 184766 110368662
Haemolysis 18.38 11.65 24 35847 15615 110537813
Haematotoxicity 18.32 11.65 28 35843 21054 110532374
PaO2/FiO2 ratio decreased 18.30 11.65 4 35867 43 110553385
Sleep disorder 17.76 11.65 23 35848 198621 110354807
Stress 17.74 11.65 6 35865 105342 110448086
Blister 17.71 11.65 29 35842 227347 110326081
Wheezing 17.69 11.65 35 35836 255195 110298233
IVth nerve paralysis 17.64 11.65 7 35864 652 110552776
Musculoskeletal pain 17.63 11.65 20 35851 183003 110370425
Alopecia 17.62 11.65 60 35811 364693 110188735
Depression 17.60 11.65 49 35822 317286 110236142
Migraine with aura 17.46 11.65 12 35859 3480 110549948
Plasma cell myeloma recurrent 17.43 11.65 16 35855 7026 110546402
Child-Pugh-Turcotte score abnormal 17.21 11.65 3 35868 8 110553420
Somnolence 17.20 11.65 45 35826 297404 110256024
Drug eruption 17.11 11.65 47 35824 53612 110499816
Renal vein thrombosis 17.07 11.65 8 35863 1117 110552311
Chest pain 16.80 11.65 64 35807 376311 110177117
Renal ischaemia 16.61 11.65 10 35861 2313 110551115
Duodenal ulcer perforation 16.49 11.65 20 35851 177680 110375748
Anterior chamber flare 16.36 11.65 5 35866 213 110553215
Cystitis haemorrhagic 16.35 11.65 20 35851 12189 110541239
Blood bilirubin increased 16.30 11.65 58 35813 75914 110477514
Contusion 16.17 11.65 32 35839 233329 110320099
Keratolysis exfoliativa acquired 16.08 11.65 3 35868 13 110553415
Pneumonitis 16.06 11.65 58 35813 76473 110476955
Brain abscess 16.01 11.65 15 35856 6759 110546669
Conjunctival hyperaemia 15.92 11.65 14 35857 5817 110547611
Balance disorder 15.90 11.65 9 35862 116551 110436877
Peripheral motor neuropathy 15.77 11.65 12 35859 4074 110549354
Colitis ulcerative 15.73 11.65 3 35868 77360 110476068
Second primary malignancy 15.70 11.65 24 35847 18044 110535384
Phaeochromocytoma crisis 15.67 11.65 6 35865 508 110552920
Pneumothorax 15.58 11.65 35 35836 35250 110518178
Erythema multiforme 15.56 11.65 26 35845 21071 110532357
Rheumatoid factor positive 15.48 11.65 12 35859 131628 110421800
Electrocardiogram high voltage 15.42 11.65 3 35868 17 110553411
Metastases to central nervous system 15.35 11.65 27 35844 22790 110530638
Rectal haemorrhage 15.31 11.65 10 35861 119823 110433605
Left ventricular dilatation 15.29 11.65 8 35863 1414 110552014
Drug-induced liver injury 15.14 11.65 78 35793 119989 110433439
Splenic abscess 14.83 11.65 7 35864 993 110552435
Hyponatraemia 14.83 11.65 121 35750 217532 110335896
Cytomegalovirus infection 14.76 11.65 45 35826 54399 110499029
Vomiting 14.73 11.65 393 35478 910282 109643146
Sleep disorder due to general medical condition, insomnia type 14.64 11.65 8 35863 105635 110447793
Cerebral venous sinus thrombosis 14.60 11.65 10 35861 2885 110550543
Alopecia areata 14.58 11.65 9 35862 2178 110551250
Intentional product misuse 14.54 11.65 13 35858 132891 110420537
Grip strength decreased 14.52 11.65 4 35867 80170 110473258
Injury 14.38 11.65 22 35849 177243 110376185
Osteonecrosis 14.37 11.65 33 35838 33708 110519720
Breast cancer stage III 14.23 11.65 4 35867 79113 110474315
Altered state of consciousness 14.13 11.65 46 35825 57580 110495848
Cardiac failure congestive 14.00 11.65 17 35854 150983 110402445
Fulminant type 1 diabetes mellitus 13.94 11.65 9 35862 2354 110551074
Beta 2 microglobulin increased 13.87 11.65 6 35865 695 110552733
Leukoencephalopathy 13.86 11.65 16 35855 9179 110544249
Malignant cranial nerve neoplasm 13.83 11.65 3 35868 31 110553397
Ureteric cancer recurrent 13.83 11.65 3 35868 31 110553397
Peripheral venous disease 13.81 11.65 5 35866 84112 110469316
Asthma 13.62 11.65 39 35832 250252 110303176
Anaphylactic reaction 13.55 11.65 73 35798 114227 110439201
Blood alkaline phosphatase increased 13.42 11.65 52 35819 70883 110482545
Dry mouth 13.36 11.65 28 35843 199920 110353508
Thrombophlebitis migrans 13.30 11.65 6 35865 768 110552660
Injection site erythema 13.24 11.65 7 35864 94169 110459259
Adverse drug reaction 13.22 11.65 9 35862 105550 110447878
Mucosal inflammation 13.21 11.65 64 35807 96077 110457351
Venous thrombosis 13.16 11.65 15 35856 8490 110544938
Gastrooesophageal reflux disease 13.06 11.65 24 35847 179952 110373476
Fibrin degradation products increased 12.96 11.65 5 35866 432 110552996
Chromosomal deletion 12.95 11.65 4 35867 177 110553251
Arteriovenous malformation 12.93 11.65 8 35863 1943 110551485
Febrile infection 12.79 11.65 11 35860 4437 110548991
Chronic obstructive pulmonary disease 12.77 11.65 10 35861 109148 110444280
Dermatitis 12.72 11.65 28 35843 27809 110525619
C-reactive protein abnormal 12.68 11.65 14 35857 129681 110423747
Type 2 diabetes mellitus 12.54 11.65 24 35847 177208 110376220
Marginal zone lymphoma stage III 12.45 11.65 3 35868 51 110553377
Laryngospasm 12.33 11.65 11 35860 4657 110548771
Secondary immunodeficiency 12.31 11.65 11 35860 4665 110548763
Metastases to liver 12.29 11.65 32 35839 35354 110518074
Gastrointestinal disorder 12.23 11.65 39 35832 241913 110311515
Ill-defined disorder 12.22 11.65 20 35851 156833 110396595
Pleural effusion 12.21 11.65 99 35772 177610 110375818
Hypertriglyceridaemia 12.03 11.65 20 35851 16134 110537294
Chest discomfort 12.03 11.65 97 35774 173751 110379677
Pneumonia cytomegaloviral 12.03 11.65 13 35858 6941 110546487
Discomfort 12.02 11.65 33 35838 214674 110338754
Macular oedema 12.01 11.65 13 35858 6953 110546475
Corneal leukoma 11.99 11.65 3 35868 60 110553368
Impaired healing 11.96 11.65 29 35842 196688 110356740
Blood pressure systolic increased 11.92 11.65 6 35865 82985 110470443
Amnesia 11.91 11.65 10 35861 105398 110448030
Heart rate decreased 11.86 11.65 6 35865 82750 110470678
Blood urea increased 11.83 11.65 42 35829 54915 110498513
Plasma cell myeloma 11.79 11.65 46 35825 62890 110490538
Lower respiratory tract infection 11.73 11.65 40 35831 243066 110310362

FDA Adverse Event Reporting System (Pediatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 9.06 8.98 3 3 1404 112543

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000932 Antiemetics
MeSH PA D000970 Antineoplastic Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018931 Antineoplastic Agents, Hormonal
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33281 antimicrobial agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35842 antirheumatic drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:63562 glucocorticoid receptor agonist
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:35442 antiparasitic agent
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:35703 xenobiotic
CHEBI has role CHEBI:35718 antifungal agent
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:37962 adrenergic agent
CHEBI has role CHEBI:38068 antimalarial
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:50671 antithyroid drug
CHEBI has role CHEBI:50857 anti-allergic agent
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:55324 gastrointestinal drug
CHEBI has role CHEBI:62868 hepatoprotective agent
CHEBI has role CHEBI:73336 vulnerary
CHEBI has role CHEBI:77715 nasal decongestant
CHEBI has role CHEBI:78298 environmental contaminant
CHEBI has role CHEBI:231911 renoprotective agent
CHEBI has role CHEBI:233423 antifibrotic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Inflammation Indication
Cattle Primary bovine ketosis Indication
Cattle Inflammation Indication
Dogs Inflammation Indication
Horses Inflammation Indication

🐶 Veterinary products

ProductApplicantIngredients
Dex-A-Vet Injection Bimeda Animal Health Limited 1
Dex-A-Vet Injection Bimeda Animal Health Limited 1
Dexamethasone Sodium Phosphate Inj. Cronus Pharma Specialities India Private Limited 1
Dexium-SP Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.75 acidic
pKa2 6.8 acidic
pKa3 11.06 acidic
pKa4 13.94 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST IC50 9.30 CHEMBL CHEMBL
Mineralocorticoid receptor Nuclear hormone receptor Ki 9.44 CHEMBL
Androgen receptor Nuclear hormone receptor Ki 5.85 CHEMBL
Progesterone receptor Nuclear hormone receptor Ki 6.25 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase IC50 9.30 CHEMBL
Inhibitor of nuclear factor kappa-B kinase subunit alpha Kinase IC50 9.30 CHEMBL
Androgen receptor Transcription factor Ki 4.79 CHEMBL
Fatty acid-binding protein, liver Cytosolic other Ki 4.66 CHEMBL
Progesterone receptor Transcription factor Ki 5.52 CHEMBL
Glucocorticoid receptor Transcription factor IC50 7.66 CHEMBL

External reference:

IDSource
4020650 VUID
N0000148296 NUI
D00975 KEGG_DRUG
312-93-6 SECONDARY_CAS_RN
4017922 VANDF
4017923 VANDF
4020650 VANDF
C0770565 UMLSCUI
DEX PDB_CHEM_ID
CHEMBL1201302 ChEMBL_ID
CHEMBL2021430 ChEMBL_ID
C004180 MESH_SUPPLEMENTAL_RECORD_UI
2BP70L44PR UNII
9400 PUBCHEM_CID
227682 RXNORM
21148 MMSL
3245 MMSL
35380 MMSL
39663 MMSL
4552 MMSL
4554 MMSL
6848 MMSL
776 MMSL
d00206 MMSL
002174 NDDF
002176 NDDF
002177 NDDF
372584003 SNOMEDCT_US
396016009 SNOMEDCT_US
396017000 SNOMEDCT_US
7561000 SNOMEDCT_US
C0011777 UMLSCUI
CHEBI:4462 CHEBI
CHEMBL384467 ChEMBL_ID
DB01234 DRUGBANK_ID
5743 PUBCHEM_CID
816 INN_ID
D003907 MESH_DESCRIPTOR_UI
CHEBI:41879 CHEBI
2BP70L44PR INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9795 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9805 INJECTION 4 mg INTRAMUSCULAR ANDA 10 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0404-9842 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0641-0367 INJECTION 10 mg INTRAMUSCULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6145 INJECTION 4 mg INTRA-ARTICULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6146 INJECTION 4 mg INTRA-ARTICULAR ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 11695-1411 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 15 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 16590-068 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 11 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 21695-847 SOLUTION 1 mg OPHTHALMIC ANDA 18 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 24208-720 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 16 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 25021-052 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 25021-053 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 13 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42254-088 SOLUTION/ DROPS 1 mg OPHTHALMIC ANDA 15 sections
Dexamethasone sodium phosphate HUMAN PRESCRIPTION DRUG LABEL 1 42571-432 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 10 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0414 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 12 sections
Dexamethasone Sodium Phosphate Human Prescription Drug Label 1 50090-0627 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-1922 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 14 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-2313 INJECTION, SOLUTION 4 mg INTRA-ARTICULAR ANDA 14 sections
DEXAMETHASONE SODIUM PHOSPHATE Human Prescription Drug Label 1 50090-3300 INJECTION, SOLUTION 4 mg INTRAVENOUS ANDA 10 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-3541 INJECTION 10 mg INTRAMUSCULAR ANDA 12 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4567 INJECTION, SOLUTION 10 mg INTRAVENOUS ANDA 9 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1297 INJECTION 4 mg SOFT TISSUE ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1343 INJECTION 10 mg INTRAVENOUS ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1370 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 13 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1391 INJECTION, SOLUTION 10 mg INTRAMUSCULAR ANDA 13 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1432 INJECTION, SOLUTION 4 mg INTRAMUSCULAR ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1541 INJECTION 100 mg INTRAMUSCULAR ANDA 10 sections
DEXAMETHASONE SODIUM PHOSPHATE HUMAN PRESCRIPTION DRUG LABEL 1 51662-1660 INJECTION 4 mg INTRAMUSCULAR ANDA 9 sections
Dexamethasone Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 54868-3129 SOLUTION 1 mg OPHTHALMIC ANDA 10 sections
DEXAMETHASONE Sodium Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 54868-6099 INJECTION 10 mg INTRAVENOUS ANDA 16 sections